Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal Surgery
NCT07751367Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of Aspergillus oryzae + Pancreatin in pancreatic exocrine insufficiency (EPI) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Gastrointestinal Symptom Rating Scale at 4 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Aspergillus oryzae + Pancreatin
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT07751367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751367.